Eli Lilly and Company
COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER

Abstract:

The present invention provides a combination of an ERK1/2 inhibitor compound, 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-- yl}-5-[2-(morpholin-4-yl) ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one, or a pharmaceutically acceptable salt thereof with gemcitabine, or a pharmaceutically acceptable salt thereof preferably hydrochloride, or with gemcitabine, or a pharmaceutically acceptable salt thereof preferably hydrochloride, and nab-paclitaxel, and to methods of using the combination to treat certain disorders, such as pancreatic cancer, including pancreatic ductal adenocarcinoma (PDAC).